83 related articles for article (PubMed ID: 18683811)
1. Prostate cancer metastases to bone: observational study for the evaluation of clinical presentation, course and treatment patterns. Presentation of the METAURO protocol and of patient baseline features.
Conti G; La Torre G; Cicalese V; Micheletti G; Ludovico MG; Vestita GD; Cottonaro G; Introini C; Cecchi M
Arch Ital Urol Androl; 2008 Jun; 80(2):59-64. PubMed ID: 18683811
[TBL] [Abstract][Full Text] [Related]
2. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices.
Freedland SJ; Richhariya A; Wang H; Chung K; Shore ND
Urology; 2012 Aug; 80(2):293-8. PubMed ID: 22748612
[TBL] [Abstract][Full Text] [Related]
4. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
[TBL] [Abstract][Full Text] [Related]
5. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
[TBL] [Abstract][Full Text] [Related]
6. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.
Gandaglia G; Karakiewicz PI; Briganti A; Passoni NM; Schiffmann J; Trudeau V; Graefen M; Montorsi F; Sun M
Eur Urol; 2015 Aug; 68(2):325-34. PubMed ID: 25108577
[TBL] [Abstract][Full Text] [Related]
7. [Clinical features of pathologically confirmed metastatic bone tumors--a report of 390 cases].
Xu DL; Zhang XT; Wang GH; Li FB; Hu JY
Ai Zheng; 2005 Nov; 24(11):1404-7. PubMed ID: 16552972
[TBL] [Abstract][Full Text] [Related]
8. Factors that predict the development of bone metastases due to prostate cancer: Recommendations for follow-up and therapeutic options.
Rodríguez-Antolín A; Gómez-Veiga F; Alvarez-Osorio JK; Carballido-Rodriguez J; Palou-Redorta J; Solsona-Narbón E; Sánchez-Sánchez E; Unda M
Actas Urol Esp; 2014 May; 38(4):263-9. PubMed ID: 24156932
[TBL] [Abstract][Full Text] [Related]
9. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
11. Our experiences in treatment of prostate carcinoma in patients over the age of 70.
Maricić A; Valencić M; Sotosek S; Spanjol J; Fuckar Z
Coll Antropol; 2011 Sep; 35 Suppl 2():199-202. PubMed ID: 22220435
[TBL] [Abstract][Full Text] [Related]
12. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE.
Ryan CJ; Elkin EP; Cowan J; Carroll PR
Cancer; 2007 Jul; 110(1):81-6. PubMed ID: 17516446
[TBL] [Abstract][Full Text] [Related]
13. Surgical management of bone metastases from urological malignancies: an analysis of 70 cases.
Toğral G; Arıkan M; Aktaş E; Öztürk R; Güven O; Eksioğlu F
Acta Orthop Traumatol Turc; 2015; 49(6):634-40. PubMed ID: 26511690
[TBL] [Abstract][Full Text] [Related]
14. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.
Ryan CJ; Elkin EP; Small EJ; Duchane J; Carroll P
Urol Oncol; 2006; 24(5):396-402. PubMed ID: 16962488
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer with bone metastasis in Beijing: an observational study of prevalence, hospital visits and treatment costs using data from an administrative claims database.
Zhuo L; Cheng Y; Pan Y; Zong J; Sun W; Xu L; Soriano-Gabarró M; Song Y; Lu J; Zhan S
BMJ Open; 2019 Jun; 9(6):e028214. PubMed ID: 31230019
[TBL] [Abstract][Full Text] [Related]
16. To treat or not to treat, that is the question: the role of bone-targeted therapy in metastatic prostate cancer.
Higano CS
J Clin Oncol; 2014 Apr; 32(11):1107-11. PubMed ID: 24590651
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.
Ost P; Decaestecker K; Lambert B; Fonteyne V; Delrue L; Lumen N; Ameye F; De Meerleer G
Prostate; 2014 Feb; 74(3):297-305. PubMed ID: 24395565
[TBL] [Abstract][Full Text] [Related]
18. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.
Hagiwara M; Delea TE; Saville MW; Chung K
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):23-7. PubMed ID: 23146970
[TBL] [Abstract][Full Text] [Related]
19. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.
Gandaglia G; Abdollah F; Schiffmann J; Trudeau V; Shariat SF; Kim SP; Perrotte P; Montorsi F; Briganti A; Trinh QD; Karakiewicz PI; Sun M
Prostate; 2014 Feb; 74(2):210-6. PubMed ID: 24132735
[TBL] [Abstract][Full Text] [Related]
20. Skeletal-related events in urological cancer patients with bone metastasis: a multicenter study in Japan.
Yokomizo A; Koga H; Shinohara N; Miyahara T; Machida N; Tsukino H; Uozumi J; Nishiyama K; Satoh F; Sakai H; Naito S
Int J Urol; 2010 Apr; 17(4):332-6. PubMed ID: 20202004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
